Findings
========

Hepatitis E virus (HEV) infection, a common cause of water-borne epidemics, is endemic and frequently responsible for acute viral hepatitis in developing countries. On the contrary, in the industrialized world, anti-HEV antibodies are detected in the general population \[[@B1]\] with no significant morbidity. Transmission is usually feco-oral, although person-to-person transmission has also been reported. Usually, an acute HEV infection is self-limiting, shows no evidence of chronic HEV infection in humans, and has a case-fatality rate of less than 0.1%. However, this disease is responsible for high maternal mortality during the third trimester of pregnancy in India while reports from Egypt, Europe and the USA have shown that the course and severity of HEV during pregnancy is no different from that observed in non-pregnant women \[[@B2]\]. No clinical case was reported in the Central African Republic until 2001 although hepatitis E (IgG) antibodies have been regularly detected in the healthy population \[[@B3]\]. The first epidemic cases of HEV in the Central African Republic were reported in 2002 \[[@B4]\] and, since then sporadic epidemic outbreaks of hepatitis E were observed. Currently in the Central African Republic, pregnant women are not routinely screened for HEV antibodies. Here, we report on cases of pregnant women who had been infected by hepatitis E in Bégoua, in the Central African Republic, in 2002. The aim of this report is to bring to the attention of health authorities the damage caused by the hepatitis E virus among pregnant women in the Central African Republic.

From July to October 2002, during an outbreak of viral hepatitis E, 21 pregnant women received prenatal care at the Maternity Center of Bégoua. The age of the patients ranged from 15 to 39 years (mean ± SD is 23.5 ± 6.3). The mean duration of gestation at admission was 29.9 ± 8.3 weeks. Two of the patients were in the first trimester, seven (7) in the second and the twelve (12) remaining in the third trimester.

The study received the ethical approval of the Scientific Committee of the Faculty of Medicine of the University of Bangui. All the patients were evaluated on the basis of history, clinical examination and liver function profile. They had no history of blood exposure or drug consumption. Initial symptoms included jaundice, fever, anorexia, asthenia, hepatomegaly and gastrointestinal pain. Biological tests were conducted on sera obtained from all patients. The levels of alanine aminotransferase were over 10 times the norm. Yellow fever and malaria tests were negative. As it was epidemic in the area at this time, acute hepatitis E was suspected but only confirmed for seven (7) women (33.3%) by ELISA (anti-HEV antibody IgM, Biokit (Sensitivity and specificity at 100%), Spain). Serology for hepatitis B and C could not be performed. Among the fourteen remaining pregnant women, eleven presented anti-HEV antibodies (IgG) showing previous contact with HEV which could not be dated. Only three pregnant women had negative HEV serology and delivered healthy babies: two at term and one at 8 months.

All seven (7) women infected by hepatitis E virus had preterm delivery. Among them three had live babies and three stillborn including one macerated. In the final case, patient 4 (Table [1](#T1){ref-type="table"}) was admitted to the Maternity Center of Begoua with a normal temperature and low blood-pressure (90/60 mm Hg). Two days later, she was evacuated to the referral hospital for metrorrhagia. She was delivered of a premature child, who died a few minutes after birth. The mother died 5 hours later of postpartum hemorrhage (Prothrombin time was 31 seconds with the control at 12.2 seconds showing that prothrombin ratio was under 15% and hemoglobin level was at 6 g/L). Although not significant, this outcome differed from the fourteen (14) other women as did the six (6) such outcomes which were observed (Table [1](#T1){ref-type="table"}). Several studies have shown that the incidence of HEV infection in pregnancy is high and a significant proportion of pregnant women can progress to fulminant hepatitis, with a high mortality rate during their third trimester \[[@B5]-[@B7]\]. In Sudan, a fatality rate of 17.8% was found during an outbreak in Darfur, with a rate of 31.1% among pregnant women \[[@B8]\]. The mechanism of severe liver injury in pregnant women with hepatitis E mortality remains a mystery \[[@B1]\]. Nevertheless, new insights into the pathophysiology of the interaction of hepatitis E and pregnancy suggest the involvement of immunology and host susceptibility factors and their interaction plays a role in disease processes \[[@B2]\].

###### 

Obstetrical, biochemical and serological data of Central African Pregnant Women with acute viral hepatitis E

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient Order   Age (years)   Gestational Number   Parity   ALAT (IU)   HEV IgM   HEV IgG   Gestational age\   Delivery\                         Weight at birth in gram   Mother status
                                                                                              (in week)          (baby status)                                               
  --------------- ------------- -------------------- -------- ----------- --------- --------- ------------------ --------------------------------- ------------------------- ---------------
  1               21            III                  I        2200        Pos       \-        33                 Premature (Macerated Stillborn)   2350                      Survived

  2               19            II                   I        1420        Pos       \-        28                 Premature (alive)                 1970                      Survived

  3               22            IV                   II       1130        Pos       \-        37                 Premature (alive)                 2630                      Survived

  4               35            VI                   V        1030        Pos       \-        32                 Premature (Died few min later)    1400                      Died

  5               20            I                    0        1260        Pos       \-        31                 Premature (alive)                 1600                      Survived

  6               20            VI                   III      980         Pos       \-        28                 Premature (Stillborn)             NA\*                      Survived

  7               18            II                   I        1380        Pos       \-        28                 Premature (Stillborn)             NA                        Survived

  8               30            I                    0        704         Neg       Pos       22                 Premature (Stillborn)             1000                      Survived

  9               35            IX                   VIII     940         Neg       Pos       22                 Miscarriage                       400                       Survived

  10              17            II                   I        700         Neg       Pos       40                 term (alive)                      NA                        Survived

  11              26            IV                   III      973         Neg       Pos       28                 Premature (alive)                 1910                      Survived

  12              33            VIII                 VI       3560        Neg       Pos       19                 Miscarriage                       NA                        Survived

  13              19            I                    0        950         Neg       Pos       28                 Premature (alive)                 NA                        Survived

  14              22            I                    0        1130        Neg       Pos       39                 term (alive)                      NA                        Survived

  15              24            IV                   III      1004        Neg       Pos       36                 Premature (alive)                 1850                      Survived

  16              16            I                    0        225         Neg       Pos       32                 Premature (alive)                 1900                      Survived

  17              30            III                  II       110         Neg       Neg       32                 Premature (alive)                 NA                        Survived

  18              18            I                    0        340         Neg       Neg       41                 term (alive)                      NA                        Survived

  19              20            II                   I        135         Neg       Pos       32                 Premature (alive)                 NA                        Survived

  20              20            I                    0        632         Neg       Neg       40                 term (alive)                      NA                        Survived

  21              15            I                    0        820         Neg       Pos       40                 term (alive)                      2300                      Survived
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* Not Available

Our study shows that the differences between these seven women consisted of their gestational number, their parity and their age. Only the 35 year old died five hours after she delivered her baby. All the other pregnant women infected were much younger (18 - 21 years old) even though some had the same gestational number as that of the deceased. This leads to the conclusion that the age of the patient might be another factor, in addition to hormonal and immunological factors, in the mechanism leading to mortality of the pregnant women in their third trimester. Our study is limited by the fact that only seven pregnant women presented acute hepatitis E and only one of them died.

Although several studies have been carried out on the factors that could be involved in the mortality of pregnant women infected by hepatitis E in their third trimester, few were related to the interactions of age/hormonal factors, age/immunological factors and age/environmental factors. It would be interesting to explore this avenue in order to decipher the influence of age on the fatal evolution of this disease among pregnant women.

Since vertical transmission risk was reported for hepatitis E virus \[[@B9]\] the death of the newborn and also the stillborn babies were likely due to the mother-child transmission by the mother who presented an acute hepatitis either during the delivery or during the third trimester of pregnancy \[[@B10]-[@B12]\]. It will also be interesting to explore this avenue in order to find better mechanisms for preventing this transmission.

In addition to the observation that a decrease in cellular immunity during pregnancy, coupled with high levels of steroid hormones, may influence hepatitis E viral replication to cause the reported high mortality \[[@B13]\], age may also be a risk factor that may have played a role in the fatal case observed. The mortality rate of hepatitis E is elevated in adults and the conjunction of age, multiparity and pregnancy should be further investigated to confirm this observation. Screening and follow up studies of pregnant women and their newborns for HEV infection are thus important for improving knowledge about the epidemiology (transmission and circulation) and transmission pathway of this virus. More extensive studies should be conducted to characterize the circulating HEV genotypes and to determine the current pathological and risk status in the general population as a whole and in pregnant women in particular in the Central African Republic.
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